

## Research Article

# Whole Genome 5'-Methylcytosine Level Quantification in Cirrhotic HCV-Infected Egyptian Patients with and without Hepatocellular Carcinoma

Ahmed M. Awad <sup>1</sup>, Wafaa S. Ragab,<sup>1</sup> Nourhan Degheidy,<sup>1</sup> and Said Ahmed Ooda<sup>2</sup>

<sup>1</sup>Chemical Pathology Department, Medical Research Institute, Alexandria University, Egypt

<sup>2</sup>Experimental and Clinical Internal Medicine Department, Medical Research Institute, Alexandria University, Egypt

Correspondence should be addressed to Ahmed M. Awad; [dr\\_amawad@hotmail.com](mailto:dr_amawad@hotmail.com)

Received 18 May 2020; Revised 26 August 2020; Accepted 20 September 2020; Published 5 October 2020

Academic Editor: Atsushi Kurabayashi

Copyright © 2020 Ahmed M. Awad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

DNA methylation is an epigenetic mechanism used by cells to control gene expression. DNA methylation is a commonly used epigenetic signaling tool that can hold genes in the “off” position. Chronic infection with hepatitis C virus (HCV) is considered a major risk for chronic liver impairment. It is the most common leading cause of HCC. The present work is aimed at studying whole genome 5'-methylcytosine levels in cirrhotic HCV-infected Egyptian patients. In the present study, 120 Egyptian adults were included. They were divided into two groups: group I (40 apparently healthy control subjects) and group II (80 HCV-infected patients). Furthermore, group II was subdivided into 2 subgroups according to the presence of HCC in HCV-infected subjects. To all studied subjects, the level of 5-mC% was measured in peripheral blood. In the present study, the median of 5'-methylcytosine% in the control group (group I) was 2.5, in the HCV group (group IIa) was 2.45, and in the HCC group (group II b) was 2.25. A stepwise decrease in 5'-methylcytosine% from the control (group I) toward HCC (group IIb) was observed, taking into consideration that the stepwise global hypomethylation was not statistically significant ( $p = 0.811$ ). There was a negative correlation between ALT and 5'-methylcytosine% ( $p = -0.029$ ). From this study, we can conclude that global DNA 5'-methylcytosine% does not differ in HCV-infected cirrhotic patients and HCC patients when compared to normal controls. Consecutively, we had concluded that there is no impact of 5'-methylcytosine% on the development of liver cirrhosis or HCC. Moreover, the negative correlation between 5'-methylcytosine% and serum ALT level denotes a trend of decrease in 5'-methylcytosine% with more liver damage.

## 1. Introduction

Epigenetics refers to heritable changes in gene expression without changes to the underlying DNA sequence. Epigenetic changes are a regular and natural occurrence, but it can also be influenced by several factors including age, environmental factors, lifestyle, and disease state [1, 2]. Disordered epigenetic gene regulation is a feature of a number of important human diseases as neurodevelopmental disorders, cardiovascular disease, and cancer [3, 4]. A number of processes have been implicated in epigenetic gene regulation

including DNA methylation, chromatin structure remodeling, histone modification, and noncoding RNAs [5].

DNA methylation refers to the addition of a methyl group (CH<sub>3</sub>) covalently to the base cytosine (C) in the dinucleotide 5'-CpG-3' [6]. Genome-wide high-resolution DNA methylblast cell line demonstrated that 67.7% of CpGs are methylated [7]. The addition of methyl groups is controlled at several different levels in cells and is carried out by a family of enzymes called DNA methyltransferases (DNMTs) [8]. DNA methylation patterns are a product of the frequency of cytosine DNA methylation at specific sites along a strand

of DNA [6]. DNA methylation occurs within the body of genes and between genes [9]. DNA methylation plays key roles in gene expression and regulation. It is an epigenetic signaling tool that locks genes in the “off position.” As in cancer cells, methylation within promoters serves to turn off critical genes (tumor suppressor genes) that could otherwise suppress tumorigenesis. It is also an important component in various cellular processes such as genomic imprinting, maintenance of chromosome stability, and X-chromosome inactivation [6]. DNA hypomethylation in cancer is as prevalent as cancer-linked hypermethylation [10]. So, the quantification of 5'-methylcytosine content or global methylation in diseased or environmentally impacted cells could provide useful information for detection of cancer [7]. Exposures to certain environmental factors can alter DNA methylation [11]. One of the questions asked while assessing the correlation between environmental exposure and epigenetic pattern is whether the pattern is a result of the exposure or it is a sign that the exposure has affected something else in the genome [12].

Hepatitis C virus (HCV) is common in the Middle East and in Africa [13]. Chronic hepatitis is known to induce changes in epigenetic machineries, including disruption of tissue and cell-specific DNA methylation patterns, resulting both in hyper- and hypomethylation of specific CPG sites [14]. These changes in turn may contribute to the exacerbation of chronic inflammation, thus producing a positive feedback loop between inflammatory and epigenetic changes which can promote proliferation and oncogenic transformation [15, 16]. HCV infection induces genome-wide, time-dependent changes in DNA methylation in infected mice with humanized livers [17]. Reactive oxygen species (ROS) induced by chronic HCV infection could change histone modification to the repressive form at CpG island-containing tumor suppressor gene promoters, leading to tumor suppressor gene inactivation. These findings suggest that chronic inflammation associated with HCV infection might cause epigenetic alterations by the immune response as well as through the induction of oxidative stress [17, 18, 19]. The precise molecular mechanism underlying HCV infection causing hepatocarcinogenesis is not fully understood. It has been proposed that HCV infection leads to hepatocarcinogenesis indirectly by viral-induced inflammation and oxidative stress. This microenvironment sets the stage for malignant transformation of hepatocytes through accumulation of both genetic and epigenetic changes [20].

To the best of our knowledge, there are no studies about the whole genome 5'-methylcytosine level in cirrhotic HCV-infected Egyptian patients which makes it noteworthy to quantitatively estimate the level of 5'-methylcytosine in the peripheral blood of the cirrhotic hepatitis C-infected Egyptian patients.

## 2. Materials and Methods

After approval of the Ethical Committee of the Medical Research Institute, Alexandria University, 120 subjects were included in the present study; patients were recruited from the Internal Medicine Department at Medical Research Insti-

tute Hospital. Informed consent was taken from all subjects who participated in the study. The subjects were divided into two groups:

- (i) Group I (control group): it consisted of 40 apparently healthy volunteers of matched age and sex with the patient group
- (ii) Group II (patient group): it consisted of 80 HCV-infected cirrhotic patients from the Internal Medicine Department at Medical Research Institute Hospital and was subdivided into 2 subgroups:
  - (a) Group IIa (HCV group): 60 cirrhotic HCV-infected patients without HCC
  - (b) Group IIb (HCC group): 20 cirrhotic HCV-infected patients with HCC

Exclusion criteria included any patient with liver disease not related to HCV or malignancies other than HCC.

To all the studied subjects, the following was done:

- (i) Detailed history taken from all subjects including history of bleeding, encephalopathy, jaundice, and ascites
- (ii) Complete physical examination done to all subjects
- (iii) X-ray chest
- (iv) Abdominal ultrasound [21]: diagnosis of liver cirrhosis was based on clinical manifestations (jaundice, spider angiomas, palmar erythema, flappy tremors, ascites, and splenomegaly), biochemical markers (reversed ALT/AST ratio, hyperbilirubinemia, hypoalbuminemia, and increased INR), and ultrasonographic features (coarse parenchymal echogenicity with a nodular pattern, small-sized liver, hypertrophy of caudate lobe, ascites, splenomegaly, portal hypertension, and presence of porto-systemic collaterals) of liver cirrhosis.

Moreover, Child-Pugh classification [22] was done for the patient group only; according to the Child-Pugh classification, patients with liver diseases were classified into 3 risk groups (A, B, and C) according to the numerical score obtained from Tables 1 and 2.

Diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients was based on multiphasic computerized tomography (CT) or dynamic contrast-enhanced magnetic resonance imaging (MRI). Diagnosis was based on the identification of the typical hallmarks of HCC which is the combination of hypervascularity in the late arterial phase (defined as arterial phase hyperenhancement (APHE) according to the Liver Imaging Reporting and Data System (LI-RADS) classification) and washout on portal venous and/or delayed phases, which reflects the vascular derangement occurring during hepatocarcinogenesis [23]. Staging of HCC was based on the Barcelona Clinic Liver Cancer (BCLC) staging system [24].

- (v) Laboratory investigations: complete blood count [25] was assayed by the Sysmex xs-800i cell counter, and plasma prothrombin activity (PT) [26] was assayed

TABLE 1: Child-Pugh scoring.

	1	2	3
Encephalopathy	None	Grades 1-2	Grades 3-4
Ascites	None	Mild/moderate	Severe
Serum albumin (g/dl)	>3.5	2.8-3.5	<2.8
Serum total bilirubin (mg/dl)	<2	2-3	>3
INR	<1.7	1.7-2.3	>2.3

TABLE 2: Child-Pugh classification.

Risk group	Numerical score
(1) Child-Pugh class A	5-6 points
(2) Child-Pugh class B	7-9 points
(3) Child-Pugh class C	10-15 points

by BFT II Siemens, while INR was calculated by the following formula:  $INR = (PT\ patient/PT\ normal)^{ISI}$ . Fasting serum glucose (FSG), albumin, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma glutamyl transferase (GGT) [27] were analyzed on the Olympus AU400 Chemistry Autoanalyzer; serodetection of HCV IgG antibody and serodetection of hepatitis B by enzyme-linked immunosorbent assay (ELISA) technique (Murex Diagnostic limited, Dartford, England) [28, 29]; estimation of AFP by

the chemiluminometric method on Immulite 1000 Siemens [30]; and HCV RNA real-time PCR [31] with the Mx3000P™ (Stratagene).

The molecular experiments that had been performed in the current study were whole genome 5'-methylcytosine level quantification [32] which included the following.

- (1) DNA extraction from peripheral blood leucocytes: DNA was purified from whole blood using the Pure-Link Genomic DNA kit for purification of genomic DNA; then, estimation of DNA concentration and purity had been done
- (2) Global DNA methylation determination kit: MethylFlash™ Methylated DNA Quantification Kit (ELISA): the MethylFlash™ Methylated DNA Quantification Kit (ELISA) contains all reagents necessary for the quantification of global DNA methylation. In this assay, DNA is bound to strip wells that are specifically treated to have a high DNA affinity. The methylated fraction of DNA is detected using capture and detection antibodies and then quantified colorimetrically by reading the absorbance in a microplate spectrophotometer. The amount of methylated DNA is proportional to the OD intensity measured.

*2.1. 5-mC Calculations.* Simple calculation of the percentage of 5-mC in total DNA can be carried out using the following formula:

$$5\text{-mC}\% = \frac{(\text{sample OD} - \text{Negative control OD}) \div \text{input sample DNA in ng}}{(\text{Positive control OD} - \text{Negative control OD}) \times 2 \div 5\text{ng}} \times 100\%. \quad (1)$$

*2.2. Statistical Analysis [33].* Data analysis was performed by using SPSS for Windows, version 20 (Statistical Package for the Social Sciences, Chicago, USA).

### 3. Results

*3.1. 5'-Methylcytosine% (Tables 3–7 and Figures 1 and 2).* Table 3 shows that there is no statistically significant difference between the control group (group I) (median = 2.5) and the patient group (group II) (median = 2.39) as regards 5'-methylcytosine% ( $p = 0.526$ ).

Table 4 and Figure 1 show that there is no statistically significant difference between studied groups as regards 5'-methylcytosine% ( $p = 0.811$ ). But there was a stepwise decrease in 5'-methylcytosine%, where in the control group, its median was 2.5; in the HCV group, its median was 2.45; and in the HCC group, its median was 2.25.

Table 5 and Figure 2 show that when HCV patients (group IIa) were subdivided according to their Child-Pugh class, there was no statistically significant difference between different classes as regards 5'-methylcytosine% ( $p = 0.443$ ).

Tables 6 and 7 show that 5'-Methylcytosine% had no statistically significant impact on development of either liver cirrhosis or HCC, as the odds ratio = 0.967 (0.887-1.054),  $p = 0.442$ , and 1.032 (0.892-1.194),  $p = 0.674$ , respectively.

There was no statistically significant correlation between 5'-methylcytosine% and any of the studied parameters such as age, AFP, HCV viral load, or Child-Pugh class with the exception of the serum ALT level.

Figure 3 shows that there was a negative significant correlation between serum ALT level and 5'-methylcytosine% in the studied groups ( $p = 0.029$ ).

### 4. Discussion

Almost 20-30% of the patients with persistent HCV infection develop liver cirrhosis within 20-30 years after infection, while the estimated incidence of HCC in those patients is 1-8% per year [34]. Thus, virus-associated hepatocarcinogenesis persists to be a serious matter, and an explanation of the mechanism of virus-associated carcinogenesis in the liver is urgently needed [35]. Epigenetic changes including DNA

TABLE 3: Statistical analysis between groups I and II as regards 5'-methylcytosine%.

	Control ( $N = 40$ )	Cases ( $N = 80$ )	Test of significance ( $p$ )
5'-Methylcytosine% median (Min-Max)	2.50 (0.079-29.36)	2.39 (0.082-22)	( $U = 1486, p = 0.526$ )

$U$ : Mann-Whitney test.

TABLE 4: Statistical analysis between studied groups as regards 5'-methylcytosine%.

	Control ( $N = 40$ )	HCV ( $N = 60$ )	HCC ( $N = 20$ )	Test of significance ( $p$ )
5'-Methylcytosine% median (Min-Max)	2.50 (0.079-29.36)	2.45 (0.08-22)	2.25 (0.16-8.86)	( $H = 0.420, p = 0.811$ )

$H$ : Kruskal-Wallis test.

TABLE 5: Statistical analysis between different Child classes in group IIa patients as regards 5'-methylcytosine level%.

	Child class A ( $N = 16$ )	Child class B ( $N = 34$ )	Child class C ( $N = 30$ )	Test of significance ( $p$ )
5'-Methylcytosine% median (Min-Max)	3.85 (0.08-17)	2.35 (0.13-22)	2.26 (0.19-8.87)	( $H = 1.630, p = 0.443$ )

$H$ : Kruskal-Wallis test.

TABLE 6: Odds ratio between the control and patient groups.

	Control group I		Case group II		OR <sup>1</sup> (95% CI <sup>2</sup> )	$p$
	No.	%	No.	%		
5'-Methylcytosine%	40	33.3	80	66.7	0.967 (0.887-1.054)	0.442

<sup>1</sup>OR: odds ratio; <sup>2</sup>CI: confidence interval.

TABLE 7: Odds ratio between the HCV group and the HCC group.

Parameter	HCV group IIa		HCC group IIb		OR <sup>1</sup> (95% CI <sup>2</sup> )	$p$
	No.	%	No.	%		
5'-Methylcytosine%	20	25	60	75	1.032 (0.892-1.194)	0.674

<sup>1</sup>OR: odds ratio; <sup>2</sup>CI: confidence interval.




FIGURE 1: Statistical analysis between studied groups as regards 5'-methylcytosine% level.

methylation and histone modifications as well as genetic aberrations are accumulated in cancer cells [36]. DNA methylation is a common epigenetic mechanism that controls

gene expression into the eukaryotic cells. DNA methylation acts as an epigenetic signaling tool that can hold genes in the "off" position [37]. Most CpG dinucleotides in the human




FIGURE 2: Statistical analysis of 5'-methylcytosine% in HCV patients with different Child-Pugh classes.




FIGURE 3: Scatter graph shows a correlation between 5'-methylcytosine and ALT.

genome are methylated. However, unmethylated CpGs are not distributed randomly but are clustered together in “CpG islands,” which are in the promoter region of many genes (the region that facilitates transcription of a particular gene) [38]. The global distribution of methylation in mammals has placed a challenge to researchers in terms of finding out whether methylation is a default state or is targeted at specific gene sequences. However, CpG islands are generally found in close proximity to transcription start sites, suggesting that there is an established recognition system [39]. A relation between chronic inflammation and DNA methylation has been suggested for a long time; however, the key factors linking them are still not completely understood [16].

Chronic liver inflammation is known to induce changes in epigenetic machineries, including disruption of tissue-

and cell-specific DNA methylation patterns, resulting in both hyper- and hypomethylation of specific CPG sites [14]. The present work is aimed at studying whole genome 5'-methylcytosine levels in cirrhotic hepatitis C-infected Egyptian patients.

In the present study, 120 Egyptian adults were included. They were divided into two groups: group I (40 apparently healthy control subjects) and group II (80 HCV-infected patients from the Internal Medicine Department of Medical Research Institute Hospital, Alexandria University). Group II was further subdivided into two subgroups: group IIa (60 HCV-infected cirrhotic patients without HCC) and group IIb (20 HCV-infected cirrhotic patients with HCC). In the present study, there was no statistically significant difference between the studied groups according to age as all the studied

groups were of comparable age. There was no significant correlation found between age and 5'-methylcytosine% ( $p = 0.356$ ).

In contrast with our study, Gomes et al. [40] stated that there was global DNA hypomethylation in the peripheral blood sample which was measured in 126 old-aged individuals by using a high-throughput ELISA-based method. In the present study, the median of 5'-methylcytosine% in the control group was 2.5%, in group IIa 2.45%, and in group IIb 2.25%. A stepwise decrease in 5'-methylcytosine% from the control group toward group IIb was observed, but taking into consideration that this stepwise global hypomethylation was not statistically significant ( $p = 0.811$ ). The forementioned finding is in agreement with the study of Wijetunga et al. [41] who isolated DNA from peripheral lymphocytes of 10 chronically HCV-infected patients and 10 HCV-negative controls. The global DNA methylation profiles of HCV-infected patients were not obviously different to those of uninfected patients ( $p > 0.05$ ), and it was supposed that these results do not support that the chronic inflammatory process itself induces DNA methylation changes as a generalized effect in the body. Also, the current study is in agreement with another study done by Okamoto et al. (2014) [17] who assessed genome-wide DNA methylation status in humanized liver mice and found no reproducible change of the DNA methylation amount in HCV-infected cells in comparison with the uninfected cells ( $p = 0.783$ ). Okamoto et al. study data demonstrated that in vitro HCV infection itself did not induce DNA methylation changes.

In contrast to our study, Nishida et al. [42] concluded that certain DNA methylation changes include global hypomethylation which already occurred in liver cirrhosis caused by HCV infection and persisted in HCC, where the mean methylation level% in normal liver tissue was 0.72, in cirrhotic liver tissue was 0.69, and in cancerous liver tissue was 0.35 ( $p < 0.001$ ). Also, several studies have shown that HCV protein could induce regional hypermethylation of specific tumor suppressor genes and it could be an important player in hepatitis virus-induced epigenetic aberrations [43, 44]. Also, DNA methylation changes with HCV viral infection were reported to be time-dependent and progresses slowly, and that global DNA hypomethylation could be one from epigenetic changes that occur from HCV viral proteins [41].

In the present study, there was more decrease in the 5'-methylcytosine% level (although it is not significant) in HCV patients suffering from more deterioration in liver function and higher degree of liver cirrhosis. When 5'-methylcytosine% levels were compared among the studied HCV-infected cirrhotic patients (group IIb) after classifying them according to Child-Pugh classes, it was found that the median of 5'-methylcytosine% in Child A patients was 3.85%, in Child B patients was (2.35%), and in Child C patients was (2.26%) ( $p = 0.443$ ).

In the present study, we found a negative correlation between ALT and 5'-methylcytosine% ( $p = 0.029$ ). In agreement with our study, Wu et al. [45] found a negative significant correlation between ALT and methylation levels. Chen

et al. [46] noted that HCC patients with a tumor size  $\geq 5$  cm showed a lower 5'-methylcytosine% content and a higher level of serum ALT. From these findings, it could be speculated that more liver damage is associated with a high ALT level and global DNA hypomethylation.

In the current study, we found by univariate logistic regression analysis that 5'-methylcytosine% is not a risk factor for liver cirrhosis development, as the odds ratio was 0.967 (0.887-1.054) and  $p = 0.442$ . Also, 5'-methylcytosine% did not have a statistically significant impact on the development of HCC where the odds ratio was 1.032 (0.892-1.194) and  $p = 0.674$ . In addition, there was no correlation between 5'-methylcytosine% and alpha fetoprotein  $p = 0.750$ . In agreement with our results, Chen et al. (2013) [46] quantified 5'-methylcytosine% in genomic DNA from HCC tumor tissue and relevant tumor adjacent normal tissues, where the mean contents of 5'-methylcytosine% in genomic DNA from matched pair tumor tissues and tumor adjacent tissues were 0.67% and 0.84%, respectively, and they concluded that hypomethylation (decreased 5'-methylcytosine%) is not associated with liver cirrhosis stages ( $p = 0.567$ ), liver inflammation stages ( $p = 0.739$ ), or tumor stages ( $p = 0.68$ ). In contrast to our study, Di et al. [47] reported that the median of 5'-methylcytosine% in HCC cases is significantly lower than that in the control group, and they concluded that the decrease in 5'-methylcytosine% has a statistically significant impact on the development of HCC, odds ratio =  $-1.9$  (1.4-2.6),  $p \leq 0.001$ . Also, Umer et al. [43] suggested that global DNA hypomethylation may be useful as a biomarker of HCC susceptibility. Also, Michailidi et al. [48] extracted DNA from frozen primary HCC and normal liver (noncirrhotic tissue obtained from autopsies) tissue samples and observed that there was statistically significant genome-wide hypomethylation in the tumor tissues when compared to normal samples.

## 5. Conclusions and Recommendations

From this study, we can conclude that global DNA 5'-methylcytosine% does not differ in HCV-infected cirrhotic patients and HCC patients compared with normal controls, denoting that the chronic HCV inflammatory process itself could not influence the global DNA methylation status and there was any correlation between age, AFP, HCV viral load, or Child-Pugh class in the studied patients and 5'-methylcytosine%; consecutively, we had concluded that there was no impact of 5'-methylcytosine% on development of liver cirrhosis or HCC.

Moreover, it had been concluded from the current study that 5'-methylcytosine% is negatively correlated with the serum ALT level, denoting a trend of decrease in 5'-methylcytosine% with more liver damage.

As the sample size may be a limitation of our study, it is recommended to reconduct the same study on a larger sample size at the peripheral blood and tissue level to minimize the probability of false-negative or false-positive results.

## Data Availability

Research data is provided in the supplementary file, and any other data will be provided whenever requested. For clinical and lab data for individual cases, refer to the supplementary file.

## Conflicts of Interest

There is no conflict of interest to be disclosed.

## Supplementary Materials

Clinical and laboratory data. (*Supplementary Materials*)

## References

- [1] P. A. Jones and D. Takai, "The role of DNA methylation in mammalian epigenetics," *Science*, vol. 293, no. 5532, pp. 1068–1070, 2001.
- [2] G. Egger, G. Liang, A. Aparicio, and P. A. Jones, "Epigenetics in human disease and prospects for epigenetic therapy," *Nature*, vol. 429, no. 6990, pp. 457–463, 2004.
- [3] M. Kaneda, M. Okano, K. Hata et al., "Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting," *Nature*, vol. 429, no. 6994, pp. 900–903, 2004.
- [4] P. A. Jones and S. B. Baylin, "The fundamental role of epigenetic events in cancer," *Nature Reviews. Genetics*, vol. 3, no. 6, pp. 415–428, 2002.
- [5] S. Mallik and U. Maulik, "miRNA-TF-gene network analysis through ranking of biomolecules for multi-informative uterine leiomyoma dataset," *Journal of Biomedical Informatics*, vol. 57, pp. 308–319, 2015.
- [6] B. Jin, Y. Li, and K. D. Robertson, "DNA methylation: superior or subordinate in the epigenetic hierarchy?," *Genes & Cancer*, vol. 2, no. 6, pp. 607–617, 2011.
- [7] R. Lister, M. Pelizzola, R. H. Dowen et al., "Human DNA methylomes at base resolution show widespread epigenomic differences," *Nature*, vol. 462, no. 7271, pp. 315–322, 2009.
- [8] K. S. Crider, T. P. Yang, R. J. Berry, and L. B. Bailey, "Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role," *Advances in Nutrition*, vol. 3, no. 1, pp. 21–38, 2012.
- [9] C. Chen, M. C. Yang, and T. P. Yang, "Evidence that silencing of the HPRT promoter by DNA methylation is mediated by critical CpG sites," *The Journal of Biological Chemistry*, vol. 276, no. 1, pp. 320–328, 2001.
- [10] M. Ehrlich, "DNA methylation in cancer: too much, but also too little," *Oncogene*, vol. 21, no. 35, pp. 5400–5413, 2002.
- [11] A. Ruiz-Hernandez, C. C. Kuo, P. Rentero-Garrido et al., "Environmental chemicals and DNA methylation in adults: a systematic review of the epidemiologic evidence," *Clinical Epigenetics*, vol. 7, no. 1, p. 55, 2015.
- [12] F. A. Champagne, "Interplay between social experiences and the genome: epigenetic consequences for behavior," *Advances in Genetics*, vol. 77, pp. 33–57, 2012.
- [13] S. M. Kamal, "Hepatitis C virus genotype 4 therapy: progress and challenges," *Liver International*, vol. 31, Suppl 1, pp. 45–52, 2011.
- [14] L. Backdahl, A. Bushell, and S. Beck, "Inflammatory signalling as mediator of epigenetic modulation in tissue-specific chronic inflammation," *The International Journal of Biochemistry & Cell Biology*, vol. 41, no. 1, pp. 176–184, 2009.
- [15] M. Martin and Z. Herceg, "From hepatitis to hepatocellular carcinoma: a proposed model for cross-talk between inflammation and epigenetic mechanisms," *Genome Medicine*, vol. 4, 2012.
- [16] M. El-Bendary, D. Nour, M. Arafa, and M. Neamatallah, "Methylation of tumour suppressor genes RUNX3, RASSF1A and E-cadherin in HCV-related liver cirrhosis and hepatocellular carcinoma," *British Journal of Biomedical Science*, vol. 77, no. 1, pp. 35–40, 2020.
- [17] Y. Okamoto, K. Shinjo, Y. Shimizu et al., "Hepatitis virus infection affects DNA methylation in mice with humanized livers," *Gastroenterology*, vol. 146, no. 2, pp. 562–572, 2014.
- [18] N. Nishida, T. Arizumi, M. Takita et al., "Reactive oxygen species induce epigenetic instability through the formation of 8-hydroxydeoxyguanosine in human hepatocarcinogenesis," *Digestive Diseases*, vol. 31, no. 5-6, pp. 459–466, 2013.
- [19] J. Lokau, V. Schoeder, J. Haybaeck, and C. Garbers, "Jak-Stat signaling induced by interleukin-6 family cytokines in hepatocellular carcinoma," *Cancers*, vol. 11, no. 11, p. 1704, 2019.
- [20] Y. Hoshida, B. C. Fuchs, N. Bardeesy, T. F. Baumert, and R. T. Chung, "Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma," *Journal of Hepatology*, vol. 61, no. 1, pp. S79–S90, 2014.
- [21] J. F. Gerstenmaier and R. N. Gibson, "Ultrasound in chronic liver disease," *Insights Into Imaging*, vol. 5, no. 4, pp. 441–455, 2014.
- [22] C. Verslype, O. Rosmorduc, P. Rougier, and Group EGW, "Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up," *Annals of Oncology*, vol. 23, Supplement 7, pp. vii41–vii48, 2012.
- [23] P. R. Galle, A. Forner, J. M. Llovet et al., "EASL Clinical Practice Guidelines: management of hepatocellular carcinoma," *Journal of Hepatology*, vol. 69, no. 1, pp. 182–236, 2018.
- [24] A. Forner, M. Reig, and J. Bruix, "Hepatocellular carcinoma," *Lancet*, vol. 391, no. 10127, pp. 1301–1314, 2018.
- [25] S. M. Lewis, B. J. Bain, and I. Bates, *Dacie and Lewis Practical Haematology Text Book*, Harcourt publishers limited, London, 9th edition, 2001.
- [26] A. Tripodi, S. H. Caldwell, M. Hoffman, J. F. Trotter, and A. J. Sanyal, "Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease," *Alimentary Pharmacology & Therapeutics*, vol. 26, no. 2, pp. 141–148, 2007.
- [27] Y. A. Lawrence and J. M. Steiner, "Laboratory evaluation of the liver," *The Veterinary Clinics of North America. Small Animal Practice*, vol. 47, no. 3, pp. 539–553, 2017.
- [28] C. Gaudy-Graffin, G. Lesage, I. Kousignian et al., "Use of an anti-hepatitis C virus (HCV) IgG avidity assay to identify recent HCV infection," *Journal of Clinical Microbiology*, vol. 48, no. 9, pp. 3281–3287, 2010.
- [29] Y. Yazdani, A. Roohi, J. Khoshnoodi, and F. Shokri, "Development of a sensitive enzyme-linked immunosorbent assay for detection of hepatitis B surface antigen using novel monoclonal antibodies," *Avicenna journal of medical biotechnology*, vol. 2, no. 4, pp. 207–214, 2010.
- [30] P. Halfon, M. Bourliere, G. Penaranda, H. Khiri, and D. Ouzan, "Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with

- chronic HCV infection,” *Journal of Clinical Microbiology*, vol. 44, no. 7, pp. 2507–2511, 2006.
- [31] Q. Zhang, X. Wang, Z. Li, and J. M. Lin, “Evaluation of alpha-fetoprotein (AFP) in human serum by chemiluminescence enzyme immunoassay with magnetic particles and coated tubes as solid phases,” *Analytica Chimica Acta*, vol. 631, no. 2, pp. 212–217, 2009.
- [32] J. Liang, X. H. Zhu, H. H. Qin et al., “A correlation study on the effects of DNMT1 on methylation levels in CD4(+) T cells of SLE patients,” *International Journal of Clinical and Experimental Medicine*, vol. 8, no. 10, pp. 19701–19708, 2015.
- [33] L. E. Daly and G. J. Bourke, *Interpretation and Uses of Medical Statistics. 5th Ed.* Oxford, Blackwell Science, Malden, Ma, 2000.
- [34] World Health Organization (WHO), *Fact sheets: hepatitis C*, 2016, September 2016, <http://www.who.int/mediacentre/factsheets/fs164/en/>.
- [35] Y. Asahina, K. Tsuchiya, T. Nishimura et al., “ $\alpha$ -Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C,” *Hepatology*, vol. 58, no. 4, pp. 1253–1262, 2013.
- [36] T. Chiba, H. Marusawa, and T. Ushijima, “Inflammation-associated cancer development in digestive organs: mechanisms and roles for genetic and epigenetic modulation,” *Gastroenterology*, vol. 143, no. 3, pp. 550–563, 2012.
- [37] D. F. Tough, P. P. Tak, A. Tarakhovsky, and R. K. Prinjha, “Epigenetic drug discovery: breaking through the immune barrier,” *Nature Reviews. Drug Discovery*, vol. 15, no. 12, pp. 835–853, 2016.
- [38] C. Vinson and R. Chatterjee, “CG methylation,” *Epigenomics*, vol. 4, no. 6, pp. 655–663, 2012.
- [39] A. M. Deaton and A. Bird, “CpG islands and the regulation of transcription,” *Genes & Development*, vol. 25, no. 10, pp. 1010–1022, 2011.
- [40] M. V. Gomes, L. V. Toffoli, D. W. Arruda et al., “Age-related changes in the global DNA methylation profile of leukocytes are linked to nutrition but are not associated with the MTHFR C677T genotype or to functional capacities,” *PLoS One*, vol. 7, no. 12, article e52570, 2012.
- [41] N. A. Wijetunga, M. Pascual, J. Tozour et al., “A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets,” *Oncogene*, vol. 36, no. 14, pp. 2030–2044, 2017.
- [42] N. Nishida, M. Kudo, T. Nishimura et al., “Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma,” *PLoS One*, vol. 8, no. 9, article e72312, 2013.
- [43] M. Umer, S. A. Qureshi, Z. Y. Hashmi et al., “Promoter hypermethylation of Wnt pathway inhibitors in hepatitis C virus - induced multistep hepatocarcinogenesis,” *Virology Journal*, vol. 11, no. 1, p. 117, 2014.
- [44] A. M. Mileo, S. Matarrocci, P. Matarrese et al., “Hepatitis C virus core protein modulates pRb2/p130 expression in human hepatocellular carcinoma cell lines through promoter methylation,” *Journal of Experimental & Clinical Cancer Research*, vol. 34, no. 1, p. 140, 2015.
- [45] H. C. Wu, Q. Wang, H. I. Yang, W. Y. Tsai, C. J. Chen, and R. M. Santella, “Global DNA methylation levels in white blood cells as a biomarker for hepatocellular carcinoma risk: a nested case-control study,” *Carcinogenesis*, vol. 33, no. 7, pp. 1340–1345, 2012.
- [46] M. L. Chen, F. Shen, W. Huang et al., “Quantification of 5-methylcytosine and 5-hydroxymethylcytosine in genomic DNA from hepatocellular carcinoma tissues by capillary hydrophilic-interaction liquid chromatography/quadrupole TOF mass spectrometry,” *Clinical Chemistry*, vol. 59, no. 5, pp. 824–832, 2013.
- [47] J. Z. Di, X. D. Han, W. Y. Gu et al., “Association of hypomethylation of LINE-1 repetitive element in blood leukocyte DNA with an increased risk of hepatocellular carcinoma,” *Journal of Zhejiang University. Science. B*, vol. 12, no. 10, pp. 805–811, 2011.
- [48] C. Michailidi, E. Soudry, M. Brait et al., “Genome-wide and gene-specific epigenomic platforms for hepatocellular carcinoma biomarker development trials,” *Gastroenterology Research and Practice*, vol. 2014, Article ID 597164, 9 pages, 2014.